Ansys Diagnostics Inc

Ansys Diagnostics Inc., a developer and manufacturer of drug testing products, will seek to raise about $25 million through an initial public offering of stock, a regulatory report said. The Lake Forest company plans to sell 2.5 million common shares at $10 to $12 each, according to the report, filed Monday with the Securities and Exchange Commission. The offering will equal about 31% of 8.01 million shares outstanding after the IPO.

Ansys Diagnostics execs decided they needed a fresh corporate identity. The Lake Forest company had acquired another firm, pushing beyond its origins as a maker of diagnostic products. A name change was clearly in order. A chance for a new start. The opportunity to overhaul the company's image. Thousands of dollars for new logos, signage, stationery, business cards. Late last month, the company announced its new moniker. Ansys Diagnostics became Ansys Technologies Inc.

Ansys Diagnostics Inc., a Lake Forest manufacturer of medical diagnostic and laboratory products, said Friday it has agreed to acquire MetaChem Technologies Inc., a Torrance company that will operate as an Ansys division and develop pharmaceutical and biotechnology products. Financial terms were not disclosed.

Ansys Diagnostics Inc., a Lake Forest manufacturer of medical diagnostic and laboratory products, said Friday it has agreed to acquire MetaChem Technologies Inc., a Torrance company that will operate as an Ansys division and develop pharmaceutical and biotechnology products. Financial terms were not disclosed.

A Lake Forest developer and manufacturer of drug testing products scrapped plans for its initial public offering of 2.5 million common shares of stock, dashing hopes of raising up to $25 million. "We are withdrawing the IPO because of market conditions," Ansys Diagnostics Inc. chief financial officer Suzanne David said Thursday. She declined to elaborate. Ansys notified the Securities and Exchange Commission in a letter July 2 that it was calling off plans for the stock offering.

Ansys Diagnostics execs decided they needed a fresh corporate identity. The Lake Forest company had acquired another firm, pushing beyond its origins as a maker of diagnostic products. A name change was clearly in order. A chance for a new start. The opportunity to overhaul the company's image. Thousands of dollars for new logos, signage, stationery, business cards. Late last month, the company announced its new moniker. Ansys Diagnostics became Ansys Technologies Inc.

A Lake Forest developer and manufacturer of drug testing products scrapped plans for its initial public offering of 2.5 million common shares of stock, dashing hopes of raising up to $25 million. "We are withdrawing the IPO because of market conditions," Ansys Diagnostics Inc. chief financial officer Suzanne David said Thursday. She declined to elaborate. Ansys notified the Securities and Exchange Commission in a letter July 2 that it was calling off plans for the stock offering.

Ansys Diagnostics Inc., a developer and manufacturer of drug testing products, will seek to raise about $25 million through an initial public offering of stock, a regulatory report said. The Lake Forest company plans to sell 2.5 million common shares at $10 to $12 each, according to the report, filed Monday with the Securities and Exchange Commission. The offering will equal about 31% of 8.01 million shares outstanding after the IPO.